Kevin McKennan, MD
Otology & Neurotology · Sacramento, CANPI 1356344022
Payments from drug & device makers
What this record shows
9 manufacturers reported payments, led by Iridex Corporation at 52.1% of the total. Reporting peaked in 2020 at $1,618 and has fallen 75.9% since, to $390 in 2025.
Across 22 payments — averaging $130.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Iridex Corporation$2K
- Cochlear Americas$471
- Inspire Medical Systems, Inc.$200
- Advanced Bionics, LLC$175
- Sanofi$120
- Regeneron Healthcare Solutions, Inc.$118
- plus $296 from 3 others
What the payments were for
- Speaking & faculty fees$1,50052%
- Food & beverage$1,38048%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Iridex Corporation | 2 | $1,500 |
| Cochlear Americas | 7 | $471 |
| Inspire Medical Systems, Inc. | 2 | $200 |
| Advanced Bionics, LLC | 6 | $175 |
| Sanofi | 1 | $120 |
| Regeneron Healthcare Solutions, Inc. | 1 | $118 |
| Integra Lifesciences Corporation | 1 | $117 |
| Intersect ENT, Inc. | 1 | $91 |
| Johnson & Johnson | 1 | $88 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,880 in reported general payments places this provider in the 60th percentile of 43 otology & neurotology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 25 | $3,294 |
| Ofloxacin | 48 | $1,303 |
| Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort | 15 | $626 |
| Clotrimazole | 13 | $300 |
| Methylprednisolone | 25 | $175 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 33 | $160 |
| Ondansetron Hcl | 49 | $155 |
| Ciprofloxacin Hcl | 15 | $118 |
| Hydrochlorothiazide | 12 | $117 |
| Diazepam | 12 | $18 |
Paid to pharmacies, not to this prescriber.
Other otology & neurotology in Sacramento
- Varun VaradarajanSacramento$27K
- Brent BenscoterSacramento$7K
- Doron SagivSacramento$981
- Hilary BrodieSacramento$400
- John Vaughanla Jolla$237K
- Rodney PerkinsWoodside$125K
- Courtney VoelkerLos Angeles$66K
- Lloyd MinorStanford$52K
- Rick Friedmanla Jolla$34K
- Sumit AgrawalStanford$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.